CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has granted stock options to Yvonne Greenstreet, the Company's newly appointed Chief Operating Officer. The compensation committee of Alnylam's board of directors approved the grant, effective as of September 19, 2016, to Dr. Greenstreet of non-qualified stock options to purchase an aggregate of 150,000 shares of Alnylam's common stock. These options were granted as an inducement material to Dr. Greenstreet's entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

The stock options have a ten-year term and an exercise price equal to $77.10, the per share closing price of Alnylam's common stock as reported by NASDAQ on the date of grant. Options to purchase 125,000 shares will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting ratably at the end of each three-month period thereafter over the remaining three years, and options to purchase 25,000 shares will vest upon the later of the one year anniversary of the date of grant and the launch of Alnylam's first internally developed product, assuming in each case Dr. Greenstreet remains continuously employed by Alnylam as of such date.

Alnylam is providing this stock option information in accordance with NASDAQ Listing Rule 5635(c)(4).